Day: August 11, 2022

Announced initiation and dosing of first patient in global Phase 3 combination trial of IO102-IO103 and KEYTRUDA® (pembrolizumab) as first-line treatment in advanced melanomaAnnounced initiation and dosing of first patient in Phase 2 Trial of IO102-IO103 in combination with KEYTRUDA® (pembrolizumab) as first line treatment in multi-cohort basket trialTwo presentations at ASCO highlighted current clinical trials with IO102-IO103 in combination with pembrolizumab and updated data cut from Phase 1/2 study of IO102-IO103 in combination with nivolumab showing high response rates in metastatic melanoma presented at AACR Strong balance sheet with $170.1 million cash runway to support multiple expected data readouts into mid-2024NEW YORK, Aug. 11, 2022 (GLOBE NEWSWIRE) — IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical...

Timber Enrolls First Patients in Phase 3 ASCEND Clinical Trial after Receiving Breakthrough Designation from FDA for Lead Asset TMB-001 BASKING RIDGE, NJ, Aug. 11, 2022 (GLOBE NEWSWIRE) — via NewMediaWire – Timber Pharmaceuticals, Inc. (“Timber” or the “Company”) (NYSE American: TMBR), a biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases, today provided a business update and announced financial results for the second quarter of 2022, ended June 30, 2022. John Koconis, Chairman and Chief Executive Officer of Timber, commented, “During the second quarter, Timber achieved several significant milestones for our lead asset, TMB-001. These include the launch and enrollment of the first patients for the pivotal Phase 3 ASCEND study, and the receipt...

EAGAN, Minn., Aug. 11, 2022 (GLOBE NEWSWIRE) — Predictive Oncology Inc. (NASDAQ: POAI) today announced the financial results for its second quarter ended June 30, 2022, which shows a strong balance sheet with a solid cash balance, commensurate equity and no debt. Highlights from the quarter include:Commercialization launch of PeDAL, our innovative AI product, and presence at BIO International that included one-on-one partnering meetings with pharmaceutical and biotech companies The appointment of Julia Kirshner, Ph.D., as Chief Scientific Officer The consolidation and expansion of the research and development arm in Pittsburgh with the move of TumorGenesis to that location An increase of cash and equivalents from $25 million on March 31, 2022, to $28 million at quarter end, which represents a positive change of 12%Q2 2022 financial...

TORONTO, Aug. 11, 2022 (GLOBE NEWSWIRE) — Shawcor Ltd. (“Shawcor” or the “Company”) (TSX: SCL) reported today its operational and financial results for the three and six months ended June 30, 2022. This press release should be read in conjunction with the Company’s Management Discussion and Analysis (MD&A) and interim consolidated financial statements for the three and six months ended June 30, 2022, which are available on the Company’s website and at www.sedar.com.  Highlights from the second quarter include:On a consolidated basis, revenue was $307.0 million, operating income was $33.7 million and Adjusted EBITDA1 was $31.5 million Composite Systems segment revenue increased by 40%, to $135 million compared with $97 million in the prior year’s quarter; Automotive and Industrial segment revenue increased by 19% to $79 million...

Consistent Performance by AIR MILES in Line with Expectations; Miles Issued Up 8% BrandLoyalty’s Financial Results Constrained by Higher Costs & Macroeconomic Headwinds, Contributing to Impairment Charge Initiatives Underway at AIR MILES and BrandLoyalty to Strengthen Market Leadership Positions and Drive Long Term GrowthSummary of Financial Results (in millions, except per share data)  Second Quarter 2022  Revenue $171.8    Net Loss* $(441.9 )  Diluted Loss Per Share* $(17.95 )  Adjusted EBITDA** $27.4    *Net Loss and Diluted EPS include approximately $428 million or $(17.32) per share of restructuring and other charges, strategic transaction costs and goodwill impairment **See “Reconciliation of Non-GAAP Financial Measures” and “Financial Measures” below for a discussion of non-GAAP financial measures. DALLAS,...

CALGARY, Alberta, Aug. 11, 2022 (GLOBE NEWSWIRE) — Condor Energies Inc. (“Condor” or the “Company”) (TSX: CPI), a Canadian based energy company with activities in Turkiye and Kazakhstan, is pleased to announce the release of its unaudited interim condensed consolidated financial statements for the three and six months ended June 30, 2022 together with the related management’s discussion and analysis. These documents will be made available under Condor’s profile on SEDAR at www.sedar.com and on the Condor website at www.condorenergies.ca. Readers are invited to review the latest corporate presentation available on the Condor website. All financial amounts in this news release are presented in Canadian dollars, unless otherwise stated. HighlightsThe Company successfully drilled and began producing the Poyraz-7 infill well in June...

Net revenue for the first half of 2022 increased 45.5% period-over-period to $42.8 million Positive results from registration-enabling study of cosibelimab in metastatic cutaneous squamous cell carcinoma presented at ASCO in June 2022; BLA submission expected YE 2022 MIAMI, Aug. 11, 2022 (GLOBE NEWSWIRE) — Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on efficiently acquiring, developing and commercializing or monetizing promising therapeutic products and product candidates, today announced financial results and recent corporate highlights for the second quarter ended June 30, 2022. Lindsay A. Rosenwald, M.D., Fortress’ Chairman, President and Chief Executive Officer, said, “Fortress ended the first half of 2022 with $42.8 million in net revenue, which is a 45.5% increase over...

CALGARY, Alberta, Aug. 11, 2022 (GLOBE NEWSWIRE) — GINSMS Inc. (TSXV: GOK) (the “Corporation”) has announced its financial results for the second quarter ended June 30, 2022. The complete financial results for GINSMS are available at www.sedar.com. Highlights include:Revenue of $630,880 for the three-month period ended June 30, 2022 as compared of $760,489 for the three-month period ended June 30, 2021. Gross Profit of $223,859 for the three-month period ended June 30, 2022 as compared to gross profit of $262,760 for the three-month period ended June 30, 2021. Operating expenses and finance costs of $228,054 for the three-month period ended June 30, 2022 increased from $142,431 for the three-month period ended June 30, 2021. Net loss of $15,149 for three-month period ended June 30, 2022 as compared to a net profit of $120,329...

Highlighted by strong profitable growthTotal revenues increased 125% year-over-year to $7.1 million, driven by ticket sales of blockbuster movies and full reopening of entertainment venues Rights for use, rental and maintenance revenues surged more than threefold year-over-year to reach a quarterly record of $2.8 million System revenues grew 69% year-over-year to $4.3 million Profit improved to $29 thousand from a loss of $1.3 million in the first quarter of 2022 Adjusted EBITDA* reached $0.6 million, positive for a fourth consecutive quarter Vesaro partners with D-BOX to equip up to 30 Formula 1® – licensed Sim Racing entertainment centres. The first site opening in London, England by the end of 2022                                                            LONGUEUIL, Quebec, Aug. 11, 2022 (GLOBE NEWSWIRE) — D-BOX Technologies...

VANCOUVER, British Columbia, Aug. 11, 2022 (GLOBE NEWSWIRE) — Glacier Media Inc. (TSX: GVC) (“Glacier” or the “Company”) reported revenue and earnings for the period ended June 30, 2022. SUMMARY RESULTS(thousands of dollars)   Three months ended June 30,   Six months ended June 30,except share and per share amounts     2022       2021       2022       2021                   Revenue   $ 43,135     $ 41,013     $ 85,367     $ 80,510  EBITDA   $ 636     $ 4,250     $ 2,876     $ 8,653  EBITDA margin     1.5 %     10.4 %     3.4 %     10.7 %EBITDA per share   $ 0.00     $ 0.03     $ 0.02     $ 0.07  Capital expenditures   $ 1,040     $ 2,060     $ 2,132     $ 3,173  Net loss attributable to common shareholder   $ (2,386 )   $ (1,902 )   $ (3,052 )   $ (171 )Net loss attributable to common shareholder per...